Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ENDOWAVE

Financiado

Cerrado

ENDObronchial microWAVE Ablation for the minimally invasive treatment of lung ca...

ENDObronchial microWAVE Ablation for the minimally invasive treatment of lung cancer Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seco... ver más

29/02/2020

ENDOWAVE

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

ENDOWAVE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2020-02-29

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

ENDOWAVE

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TABLA Development and Commercialisation of Transbronchial Lung Abl... 4M€ Cerrado

DRAIOCHT DRAIOCHT A low cost minimally invasive platform medical dev... 130K€ Cerrado

Go-Smart A Generic Open end Simulation Environment for Minimally Inva... 5M€ Cerrado

LASER OPTIMAL Laser Ablation SElectivity and monitoRing for OPTImal tuMor... 1M€ Cerrado

FIBERSTAR FIBER optic sensors for Smart Thermal Ablation at Radiofrequ... 158K€ Cerrado

TEC2013-48251-C2-2-R PLANIFICACION Y GUIADO MULTIMODAL EN CIRUGIA Y TRATAMIENTO D... 93K€ Cerrado

Duración del proyecto: 2 meses Fecha Inicio: 2019-12-03
Fecha Fin: 2020-02-29

Líder del proyecto

ENDOWAVE LIMITED No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Lung cancer is the most common cause of cancer deaths in the EU and worldwide with more than 0.4M people diagnosed each year. It has a dismal 5 year survival rate of just 18% and worldwide someone dies of lung cancer every 30 seconds. The impact of the disease on public health is substantial with > 6M hospital admissions in Europe each year (>€18 billion in economic costs). Surgery has been shown to provide a curative solution, but only 20-30% of patients can undergo surgery due to co-morbidities. ENDOWAVE have developed a pioneering device, designed to destroy the targeted tumour in a single, minimally invasive intervention. The patented technology uses a flexible catheter system, which can be navigated through the patient’s airway to deliver targeted microwave heating to the tumour. This will enable physicians provide a curative treatment that can be delivered in an outpatient setting, improving patient outcomes and reducing costs to healthcare system. The global market opportunity for lung cancer exceeds €3.6 billion. This SME Phase 1 Instrument funding will enable ENDOWAVE to complete detailed feasibility and business planning activities that will provide a platform for commercialisation of the technology. This will enable ENDOWAVE to enter the market, where we forecast revenues of €60 million by Year 5 based on conservative market penetration forecasts. This project will lead to job generation within ENDOWAVE and the associated supply chain. Ultimately, ENDOWAVE seeks to improve outcomes for lung cancer patients by providing a curative treatment, which can be delivered in a single minimally invasive procedure.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores